Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor Fitzgerald
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255
Alnylam Pharmaceuticals Analyst Ratings
JPMorgan Chase Raises Price Target on Alnylam Pharmaceuticals to $248 From $160
Alnylam Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target
Alnylam Pharmaceuticals Analyst Ratings
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Strong Financial Growth and Promising Clinical Trials Bolster Buy Rating for Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Analyst Ratings
Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings